86 reports of this reaction
2.2% of all GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE reports
#7 most reported adverse reaction
DYSPNOEA is the #7 most commonly reported adverse reaction for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, manufactured by RB Health (US) LLC. There are 86 FDA adverse event reports linking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE to DYSPNOEA. This represents approximately 2.2% of all 3,854 adverse event reports for this drug.
Patients taking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 86 FDA reports for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.2% of all adverse event reports for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, making it a notable side effect.
If you experience dyspnoea while taking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.